#None #Argo Biopharma #siRNA therapeutics #BW-50218

Argo Biopharma Begins Phase I Study of siRNA Therapeutic BW-50218

Argo Biopharmaceutical Co., Ltd., a leader in clinical-stage biotechnology, has officially announced the commencement of its Phase I clinical trial for the siRNA therapeutic agent known as BW-50218. This milestone, reached on April 28, 2026, in Australia, represents a crucial step forward in the development of next-generation therapies targeting transthyretin protein (TTR).

What is BW-50218?

BW-50218 is engineered using Argo Biopharma's proprietary RADS™ platform, designed to deliver potent and durable gene silencing with improved safety and delivery characteristics, specifically through hepatic delivery. This therapeutic aims to offer innovative treatment options for a variety of diseases, particularly addressing cardiovascular and specialty conditions. The company maintains an active pipeline that includes both hepatic and extra-hepatic siRNA candidates.

Clinical Trial Details

The ongoing Phase I trial (NCT07401472) employs a randomized, double-blind, placebo-controlled methodology. This single ascending dose study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of BW-50218 administered subcutaneously. Researchers will evaluate various safety and biological activity markers to elucidate the pharmacologic profile of this siRNA therapeutic and its potential for future development.

Dr. Dongxu Shu, Co-Founder, Chairman, and CEO of Argo Biopharma, expressed optimism regarding this milestone, stating, “We are pleased to have dosed the first subject in our Phase 1 trial of BW-50218. Our collaboration with Novartis, which shares our commitment to advancing therapies for patients with unmet medical needs, solidifies our shared mission.” This partnership is set to include milestone payments that will further boost Argo Biopharma's research and development initiatives already focused on their hepatic and extra-hepatic siRNA portfolio.

Future Prospects

With BW-50218 entering clinical trials, Argo Biopharma showcases its robust capabilities in progressing innovative therapeutics from discovery to the clinical stage. This move positions the company as a key player in the biopharmaceutical landscape, aiming to address pressing medical needs through their advanced RNAi solutions. Currently, Argo has a diverse pipeline that includes seven RNAi candidates in various stages of clinical development, enhancing its objective to deliver better health outcomes globally.

The trial's participants will be critical in determining the therapeutic potential of BW-50218, and the results may pave the way for new treatments for conditions that are currently difficult to manage. The expertise of Argo Biopharma in both discovery and clinical development will surely play a vital role in shaping the future of RNAi therapeutics.

For more details regarding Argo Biopharmacology and its progressive research initiatives, visit www.argobiopharma.com.